Results 61 to 70 of about 6,218 (156)

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.

PLoS ONE
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety.
Ji Sun, Xuanyu Deng, Juanjuan Huang, Gefei He, Shiqiong Huang   +4 more
doaj   +1 more source

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19

Microbiology Spectrum
Immunocompromised individuals are susceptible to severe coronavirus disease 2019 and potentially contribute to the emergence of variants with altered pathogenicity due to persistent infection.
Rebekah Penrice-Randal, Eleanor G. Bentley, Parul Sharma, Adam Kirby, I'ah Donovan-Banfield, Anja Kipar, Daniele F. Mega, Chloe Bramwell, Joanne Sharp, Andrew Owen, Julian A. Hiscox, James P. Stewart   +11 more
doaj   +1 more source

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Immunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen   +7 more
doaj   +1 more source

Selective Inhibition of Vascular Smooth Muscle Cell Function by COVID-19 Antiviral Drugs: Impact of Heme Oxygenase-1

Antioxidants
Coronavirus disease 2019 (COVID-19) causes cardiovascular complications, which contributes to the high mortality rate of the disease. Emerging evidence indicates that aberrant vascular smooth muscle cell (SMC) function is a key driver of vascular disease
Kelly J. Peyton, Giovanna L. Durante, William Durante   +2 more
doaj   +1 more source

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019

Viruses
Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat to the immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance to severe
Chie Yamamoto, Masashi Taniguchi, Keitaro Furukawa, Toru Inaba, Yui Niiyama, Daisuke Ide, Shinsuke Mizutani, Junya Kuroda, Yoko Tanino, Keisuke Nishioka, Yohei Watanabe, Koichi Takayama, Takaaki Nakaya, Yoko Nukui   +13 more
doaj   +1 more source

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

Infection and Drug Resistance
Na Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N, Yu X, Li L, Yang P, Dong R, Huang Y, Ling X, Shentu Q, Yu W, Jiang S   +9 more
doaj  

Deriving M-polynomial Based Topological Descriptors of Oral Antiviral Clinical Drug Nirmatrelvir

Scientific Annals of Computer Science
The novel human coronavirus known as SARS-CoV-2 poses a serious risk to human health. Regretfully, the US Food and Drug Administration (FDA) has approved very few oral antiviral medications for the treatment of COVID-19 patients. In the current study, we
Shibsankar Das, Modhuleena Mandal
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

Nirmatrelvir-Ritonavir-Induced Pancreatitis: A Concern in the COVID Era. [PDF]

ACG Case Rep J
DeBroff J, Abraham J, Yoon BH, Cohen I.
europepmc   +1 more source